MARKET

GSK

GSK

GSK PLC
NYSE
41.11
+0.20
+0.49%
After Hours: 41.00 -0.11 -0.27% 16:38 04/26 EDT
OPEN
40.95
PREV CLOSE
40.91
HIGH
41.31
LOW
40.87
VOLUME
2.55M
TURNOVER
0
52 WEEK HIGH
43.84
52 WEEK LOW
32.35
MARKET CAP
83.99B
P/E (TTM)
13.47
1D
5D
1M
3M
1Y
5Y
EXPLAINER-What to know about bird flu in dairy cows and the risk to humans
First known outbreak of bird flu in dairy cows has spread to 33 herds in eight states in the U.S. Only one person has tested positive for H5N1, and the risk to humans is low. The virus has spread through the milk supply in the country's milk supply. Scientists say the virus could spread to humans.
Reuters · 23h ago
BUZZ-Pfizer, BioNTech fall as GSK sues over COVID-19 vaccine technology
GlaxoSmithKline sues vaccine makers Pfizer and BioNTech over COVID-19 vaccine technology. GSK accuses them of infringing its patents related to messenger RNA technology in the companies' blockbuster vaccines. Shares of vaccine makers fall between 2% and 3%.
Reuters · 1d ago
UPDATE 3-GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology. Company accuses them of infringing GSK patents related to messenger RNA technology in the companies' blockbuster vaccines. GSK says the vaccines violate the company's patent rights in mRNA-vaccine innovations.
Reuters · 1d ago
Weekly Report: what happened at GSK last week (0415-0419)?
Weekly Report · 4d ago
EUROPE RESEARCH ROUNDUP-Alfen, Boliden, Pennon Group
Alfen, Boliden, Pennon Group revise their ratings and price targets on several European companies. Securities analysts revise ratings and target prices on companies including Adidas, Airbus and Akzo Nobel. A number of analysts raise their ratings on Adidas and Asos, while others cut their targets.
Reuters · 04/17 07:09
BRIEF-GSK Announces Results From Long-Term Data Relating To Shingrix
GSK Announces Results From Long-Term Data Relating To Shingrix. Results from long-term data show 79.7% EFFICACY in 50-plus year old people. No new safety concerns were identified from the data. GSK plc: Results from data relate to shingrix.
Reuters · 04/17 06:15
BRIEF-GSK Announces Additional Eagle-1 Results
GSK Announces Additional Eagle-1 Results. GSK says data show potential for GEPOTIDACIN as a new oral treatment option. The company says the drug has a 92.6% success rate in clinical trials for a new treatment for rheumatology.
Reuters · 04/17 06:14
Health Rounds: RSV infection raises heart risk in unvaccinated adults
Health Rounds: RSV infection raises heart risk in unvaccinated adults raises heart risks. Cardiac events are common among older un vaccinated adults who are hospitalized with respiratory syncytial virus. Heart failure from cancer drugs may be preventable, researchers say. The study looked at the effects of RSV and cancer drugs known as anthracyclines.
Reuters · 04/16 19:05
More
About GSK
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.

Webull offers GSK plc (ADR) stock information, including NYSE: GSK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GSK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GSK stock methods without spending real money on the virtual paper trading platform.